Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30233095 | 0.79 | PIK3CG (0.38) | MAPK14PIK3CGBRD4 | |
| SCHEMBL24003865 | 0.79 | PIK3CG (0.38) | MAPK14PIK3CGBRD4 | |
| SCHEMBL26322957 | 0.77 | CYP11B2 (0.46) | PIK3CGNPC1RAB9ACYP11B1CYP11B2 | |
| SCHEMBL24004079 | 0.75 | MAPK14 (0.43) | MAPK14PIK3CGNPC1RAB9ACYP11B1 | |
| SCHEMBL24003963 | 0.74 | MAPK14 (0.52) | MAPK14NPC1RAB9ACYP11B1CYP11B2 | |
| SCHEMBL14259445 | 0.73 | NPC1 (0.67) | NPC1RAB9ACYP11B1CYP11B2CYP2D6 | |
| SCHEMBL25820860 | 0.71 | UGCG (0.38) | PIK3CGNPC1RAB9ACYP11B1CYP11B2 | |
| SCHEMBL26321765 | 0.70 | MAPK14 (0.54) | MAPK14NPC1RAB9ACYP11B1CYP11B2 | |
| SCHEMBL28883282 | 0.68 | NPC1 (0.68) | NPC1RAB9ACYP11B2CYP2D6PKM | |
| SCHEMBL26315347 | 0.67 | MAPK14 (0.40) | MAPK14PIK3CGNPC1RAB9ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | MAPK14 258/4885PIK3CG 18/4885HSPB1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.